New radioactive drug targets childhood cancers that Won't quit
NCT ID NCT03478462
First seen Mar 22, 2026 · Last updated Jun 21, 2026 · Updated 17 times
Summary
This early-stage trial tests a radioactive drug called CLR 131 in 30 children and young adults with solid tumors, lymphoma, or brain tumors that have come back or not responded to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. Participants receive the drug through an IV, and doctors monitor for side effects and any signs of cancer control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's Hospital at Westmead
Westmead, New South Wales, 2145, Australia
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229, United States
-
Duke University
Chapel Hill, North Carolina, 27708, United States
-
Hospital for Sick Children
Toronto, Ontario, M5G1X8, Canada
-
Lucile Packard Children's Hospital
Palo Alto, California, 94304, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Texas Children's Hospital
Houston, Texas, 77030, United States
-
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, 53792, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CLR 131 (a radioactive drug that targets cancer cells)
What this could lead to
If it works, this could point toward a new treatment option for children with cancers that have not responded to standard therapies.
What could go wrong
This is an early Phase 1 trial with only 30 participants, so it is too small to prove effectiveness. The drug is radioactive and may cause side effects like damage to healthy tissues.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.